A tier · strong
Parenteral B12 is a licensed, unambiguously effective treatment for deficiency caused by malabsorption, but the comparative evidence for the injectable route over oral is low-certainty and there is no evidence at all for the energy and weight-loss claims under which it is usually sold.
injectable vitamin b12
Injectable cobalamin bypasses intrinsic-factor-dependent absorption and reliably corrects vitamin B12 deficiency, including pernicious anaemia, where oral absorption is impaired. Its benefit in people with normal B12 status — the population most cosmetic and wellness marketing targets — is not supported by the evidence.
the explanation
B12 injections genuinely work for people who cannot absorb B12 from food, such as those with pernicious anaemia or after stomach or bowel surgery. For people whose B12 levels are already normal, the shots have not been shown to improve energy or help with weight.
regulatory status
Approved / licensed
Cyanocobalamin injection USP is a long-marketed FDA-regulated prescription product with numerous US labellers including Hikma, Fresenius Kabi, American Regent and Meitheal. In the UK, hydroxocobalamin injection is the licensed form for B12 deficiency; NICE's 2024 evidence review positions intramuscular hydroxocobalamin as first-line, often lifelong, for malabsorptive causes. Methylcobalamin injection is licensed in Japan and India but is not an FDA-approved drug in the US.
how it works · proposed mechanism
Cobalamin acts as an enzymatic cofactor in two reactions, and the injectable route exists purely to bypass a broken absorption pathway.
Methionine synthase cofactor
Methylcobalamin is the cofactor for methionine synthase, which converts homocysteine to methionine and releases tetrahydrofolate from the 5-methyl trap. Loss of this reaction produces the megaloblastic anaemia and elevated homocysteine of B12 deficiency.
Methylmalonyl-CoA mutase cofactor role
Adenosylcobalamin is the cofactor for methylmalonyl-CoA mutase, which routes odd-chain fatty acid and branched amino acid catabolites into the TCA cycle. Its failure raises methylmalonic acid and is implicated in the neurological manifestations of deficiency.
Bypassing intrinsic factor
Dietary B12 requires gastric intrinsic factor and cubilin-mediated ileal uptake, both of which are lost in pernicious anaemia and after gastric or ileal surgery. Injection delivers cobalamin directly to plasma, where it binds transcobalamin II for cellular delivery.
what’s reported
evidence shape
5 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
The condition the injection genuinely treats — malabsorptive B12 deficiency — is diagnosable by blood testing, and outside that population the evidence for benefit collapses. NIH ODS states plainly that B12 supplementation appears to have no beneficial effect on performance in the absence of a nutritional deficit, which is precisely the claim wellness clinics make for it.
key published findings
- Official / human: NICE's 2024 evidence review on vitamin B12 replacement concluded that intramuscular hydroxocobalamin is preferred, often lifelong, for deficiency caused by malabsorption such as autoimmune gastritis or gastrointestinal surgery, while oral cyanocobalamin is considered first-line for dietary deficiency; underlying evidence was rated very low to moderate quality.
- Human trial: Cochrane review (2018) of 3 RCTs and 153 participants (74 oral, 79 intramuscular) found no clinically relevant difference in serum B12 between routes at 1000 mcg/day oral, with results favouring oral at 2000 mcg/day; no included trial measured fatigue, neurological symptoms or quality of life, and certainty was low to very low.
- Observational: NHANES-based estimates reported by NIH ODS put clinical deficiency (serum B12 under 200 pg/mL) at approximately 3.6% of US adults, with insufficiency (under 300 pg/mL) affecting roughly 12.5% of adults aged 19 and over.
- Official: NIH ODS states that vitamin B12 supplementation 'appears to have no beneficial effect on performance in the absence of a nutritional deficit', and that the Food and Nutrition Board set no Tolerable Upper Intake Level because of B12's low toxicity potential.
- Human / health economics: the NICE committee noted parenteral replacement becomes cost-effective only after approximately six months of treatment, and that improvements in haematological values do not necessarily translate into improved quality of life.
limitations of the evidence
- Randomised comparative evidence between injectable and oral routes totals fewer than 200 participants across three small trials, none of which measured symptomatic or functional outcomes.
- Almost no trial evidence exists in B12-replete populations, so claims about energy, mood or weight rest on absence of evidence rather than on demonstrated benefit.
- Serum B12 is an imperfect biomarker; methylmalonic acid and homocysteine better identify functional deficiency, and studies using serum B12 alone may misclassify both deficiency and response.
documented safety signals
- Hypokalaemia and thrombocytosis can occur during correction of severe megaloblastic anaemia as haematopoiesis resumes.
- Rare anaphylactic and hypersensitivity reactions to cobalamin injections, including to cobalt and to benzyl alcohol in multi-dose preparations, are documented.
- Injection-site pain and, uncommonly, acneiform or rosacea-like eruptions have been reported with repeated parenteral cobalamin.
- Cyanocobalamin contains a cyanide moiety and is generally avoided in Leber's hereditary optic neuropathy and in tobacco amblyopia, where hydroxocobalamin is preferred.
- Treating a B12-replete person masks nothing but also achieves nothing, and injections given without testing can obscure an untreated underlying cause of deficiency.
identity
| full name | Injectable vitamin B12 (cyanocobalamin / methylcobalamin / hydroxocobalamin) |
| category | Nutritional |
| modality | small molecule |
| formula | C63H88CoN14O14P |
| molar mass | 1355.4 g/mol |
| cas | 68-19-9 |
laboratory handling
| storage | Cobalamin injection solutions are stored at controlled room temperature, typically 20-25 C, and protected from light because cobalamins are photolabile; solutions are red and should not be used if colour has faded. |
| solubility | Cyanocobalamin is freely soluble in water (approximately 1 in 80) and formulated as a simple aqueous solution; hydroxocobalamin is also water-soluble but binds plasma proteins more tightly, which gives it longer retention after injection. |
| co-studied with | Cyanocobalamin is a common additive to compounded lipotropic blends, where it contributes the characteristic red colour and a separate 'energy' marketing claim; there is no controlled evidence that adding it to such a blend affects body composition. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
5 citedNational Institute for Health and Care Excellence · 2024 · official
NIH Office of Dietary Supplements · 2025 · official
DailyMed, U.S. National Library of Medicine · 2026 · official
Cochrane Database of Systematic Reviews · 2018 · reviews
others in Nutritional